Cingulate Inc., a biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 2,000,000 shares of common stock by Lincoln Park Capital Fund, LLC. The shares are par value $0.0001 per share and may be sold at Lincoln Park's discretion. The Purchase Agreement, dated April 24, 2023, allows Cingulate to issue and sell shares to Lincoln Park from time to time. Cingulate will not sell any securities under this prospectus nor receive proceeds from Lincoln Park's resale. However, Cingulate may receive up to $11,395,028.72 from the sale of Purchase Shares to Lincoln Park, subject to conditions. The selling price of the shares will fluctuate based on Cingulate's common stock trading price. The prospectus also states that Lincoln...Show More

Cingulate Inc., a biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 2,000,000 shares of common stock by Lincoln Park Capital Fund, LLC. The shares are par value $0.0001 per share and may be sold at Lincoln Park's discretion. The Purchase Agreement, dated April 24, 2023, allows Cingulate to issue and sell shares to Lincoln Park from time to time. Cingulate will not sell any securities under this prospectus nor receive proceeds from Lincoln Park's resale. However, Cingulate may receive up to $11,395,028.72 from the sale of Purchase Shares to Lincoln Park, subject to conditions. The selling price of the shares will fluctuate based on Cingulate's common stock trading price. The prospectus also states that Lincoln Park is considered an 'underwriter' within the meaning of the Securities Act of 1933. Cingulate's common stock and warrants are listed on Nasdaq under the symbols 'CING' and 'CINGW,' respectively. The last reported sale prices for the common stock and warrants were $0.8051 per share and $0.025 per warrant, respectively. Cingulate is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements. The prospectus date is May 23, 2024.